PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1403524
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1403524
According to Stratistics MRC, the Global Dual-energy X-ray Absorptiometry (DEXA) Market is accounted for $619.52 million in 2023 and is expected to reach $1207.27 million by 2030 growing at a CAGR of 10.0% during the forecast period. Bone mineral density (BMD) and body composition can be measured with accuracy and without invasiveness using dual-energy X-ray absorptiometry (DEXA). DEXA provides precise information about an individual's skeletal health and overall body composition by using low-dose X-ray beams at two different energy levels to differentiate between bone, fat, and lean tissue. DEXA scans are frequently used to evaluate osteoporosis and are useful in determining fracture risk and bone mineral loss.
According to the International Osteoporosis Foundation, around one in three women and one in five men over the age of 50 are suffering from osteoporosis. The organization also estimated that over 75 million patients are associated with osteoporosis in the U.S., Europe, and Japan.
Age-related bone loss, or osteoporosis, is becoming more common as the world's senior population grows. DEXA is essential for diagnosing this vulnerability because it is a critical diagnostic tool that enables prompt interventions to avoid fractures and associated complications. Additionally, regular DEXA scans are required for the ongoing health management of the aging population, which encourages an early approach to senior healthcare.
Healthcare facilities may face financial difficulties with the initial capital expenditure for DEXA equipment as well as continuing maintenance costs. The cost of all this is influenced by the complex technology and constant calibration needed to ensure accuracy. Furthermore, this financial factor highlights the need for financial considerations in healthcare planning and may prevent DEXA from being widely adopted, particularly in settings where resources are scarce.
Beyond clinical diagnostics, DEXA can be used in research applications and is a useful tool for evaluating how medications affect bone health. Moreover, its function in tracking alterations in the composition and density of bone offers vital information for medication development, enabling more effective and focused treatments for diseases like osteoporosis. Opportunities for more research in this area are provided by partnerships between pharmaceutical companies and academic institutions.
Emerging alternative technologies and changing competitive landscapes pose threats to the DEXA market. The dominance of DEXA in the market is threatened by competing diagnostic modalities like quantitative computed tomography (QCT) and peripheral quantitative computed tomography (pQCT). Additionally, market share and adoption rates may be impacted if ongoing developments in alternative technologies draw capital and attention away from conventional DEXA systems.
The market for dual-energy X-ray absorptiometry (DEXA) has been greatly impacted by the COVID-19 pandemic. Routine diagnostic procedures, such as DEXA scans, have decreased as a result of disruptions to healthcare services, the reallocation of resources to address pandemic-related challenges, and increased safety concerns. Furthermore, the adoption of DEXA technology has temporarily stalled due to a combination of factors, including fewer patient visits to healthcare facilities, delays in non-urgent medical appointments, and financial constraints on healthcare budgets. But the pandemic has also highlighted the value of preventive healthcare, which may present prospects for DEXA's comeback as long as healthcare systems give regular screenings and diagnostic procedures top priority during the post-pandemic recovery period.
It is projected that axial DEXA bone densitometers will command the largest market share in dual-energy X-ray absorptiometry (DEXA). These instruments are mainly used to assess the bone mineral density in the hip and spine, which are important regions to assess the risk of fractures and osteoporosis. Axial DEXA scans help physicians diagnose diseases like osteoporosis and evaluate the efficacy of treatments by giving them extremely precise and comprehensive information about bone health. Moreover, clinicians in a variety of healthcare settings prefer the axial configuration because it enables a thorough examination of central skeletal sites. As osteoporosis becomes more common and bone health becomes more important, axial DEXA bone densitometers will always be essential for managing diseases and providing preventive care.
The market for dual-energy X-ray absorptiometry (DEXA) is expected to grow at the highest CAGR in the body composition analysis segment. The market for advanced diagnostic tools has been driven by growing awareness of the influence of body composition on overall health, fitness, and disease prevention. Beyond conventional bone density tests, body composition analysis offers a thorough analysis of lean muscle mass, fat distribution, and other important factors. Additionally, in order to address the global concerns surrounding obesity, metabolic disorders, and conditions that cause muscle wasting, technology is essential.
With the largest share, North America has continued to hold a dominant position in the dual-energy X-ray absorptiometry (DEXA) market. Particularly in the United States, the healthcare industry is well-established and technologically sophisticated, with large expenditures made in medical research, state-of-the-art equipment, and a vast infrastructure. Furthermore, the prominence of the region is emphasized by the high level of healthcare spending, the strong regulatory environment, and the ongoing emphasis on innovation. Because of this, North America-led by the United States-continues to have a significant influence on how the global healthcare sector develops.
The Asia-Pacific region is expected to have the highest CAGR over the projected period. Growing investments in healthcare infrastructure, an aging population with evolving healthcare needs, and growing healthcare awareness are all factors contributing to this notable growth. Leading nations in the advancement of pharmaceuticals, medical technology, and healthcare services are China, India, and Japan. Additionally, the region's emphasis on digital health solutions, along with encouraging government initiatives, positions Asia-Pacific as a major hub for the changing healthcare landscape and contributes significantly to the market's rising compound annual growth rate.
Some of the key players in Dual-energy X-ray Absorptiometry (DEXA) market include Osteometer Meditech Inc, Medilink International, GE Healthcare, Shenzhen XRAY Electric Co., Ltd., BeamMed Ltd, Furuno Electric Co., Ltd., Hologic, Inc., Scanflex Healthcare AB, Medonica Co., Ltd, Fonar Corporation and Swissray Medical AG.
In December 2023, GE Healthcare has entered into a distribution agreement with mobile-first clinical surveillance technology provider, AirStrip to expand AirStrip Cardiology and Patient Monitoring solutions in the US. The mobile application from AirStrip enables clinicians to view clinical data on the web and on mobile devices. It connects with cardiac rhythm strips and 12-lead ECGs, allowing clinicians to monitor numerous patients at the same time and can receive STEMI notifications.
In October 2023, MediLink Therapeutics, announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE, a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, on the development of a next-generation antibody-drug conjugate candidate ("ADC"), against Human Epidermal Growth Factor Receptor 3 (HER3).
In September 2023, Hologic Inc. and Bayer today announced an international partnership to deliver contrast-enhanced mammography (CEM) solutions to improve the detection of breast cancer for women in multiple countries across the European, Canadian and Asia Pacific regions. CEM is a highly sensitive and relatively low-cost breast imaging modality that combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.